Fundraising Fox
Monte Rosa Therapeutics
NASDAQ: GLUEBoston, US · Founded 2019 · Delaware corporation · 227 employees on LinkedIn · 11 known investors
Find your way into Monte Rosa Therapeutics
Sign up to see every warm intro you have to Monte Rosa Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Monte Rosa Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.
Founders & leadership
Board
Investors · 11
How we know: Aisling Capital's portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · HBM Partners's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: the company's own site · the S-1 prospectus · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Versant Ventures's portfolio page · the company's own site · the S-1 prospectus · a partner's Signal profile · Not right? Tell us
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$143M disclosed across 2 of 5 rounds · 1900–2021
▶$95MraisedMar 2021 · 23 investors · BiotechnologyRule 506(b)
- Markus WarmuthExecutive Officer, Director
- Alexander MaywegDirector
- Bradley BolzonDirector
- Ali BehbahaniDirector
- Kim BlackwellDirector
- Drew SchiffDirector
- Chandra P. LeoDirector
- Christine SiuDirector
- Ajim TamboliExecutive Officer
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$48MraisedSep 2020 · 17 investors · BiotechnologyRule 506(b)
- Alexander MaywegDirector
- Bradley BolzonDirector
- Markus WarmuthExecutive Officer, Director
- Ali BehbahaniDirector
- Kim BlackwellDirector
- Offering amount
- $96M
- Amount sold
- $48M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Monte Rosa Therapeutics.
Frequently asked questions
- What does Monte Rosa Therapeutics do?
- Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.
- Who are Monte Rosa Therapeutics's investors?
- Monte Rosa Therapeutics's investors include Aisling Capital, HBM Partners, New Enterprise Associates (NEA), Versant Ventures, Amzak Health, Avoro Capital Advisors, GV (Google Ventures), HBM Healthcare Investments and 3 more.
- How much funding has Monte Rosa Therapeutics raised?
- Monte Rosa Therapeutics has disclosed $143M raised across 2 of its 5 known rounds.
- Where is Monte Rosa Therapeutics headquartered?
- Monte Rosa Therapeutics is headquartered in Boston, US.